Google
CRBU — CARIBOU BIOSCIENCES INC (Healthcare >> Biotechnology)
CRBU FAQ
What is CRBU's ROE?
CARIBOU BIOSCIENCES INC reports a Return on Equity (ROE) of -130.58%.
What is CRBU's dividend yield?
CARIBOU BIOSCIENCES INC offers a dividend yield of 0.00%.
What is CRBU's Deepscope Quality Score?
Deepscope rates CRBU's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CRBU?
Deepscope's AI Timing Score for CRBU is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CRBU belong to?
CARIBOU BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.84
Price
-0.05
(-2.72%)
Day Change
|
|
|---|
CRBU Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.84 |
| PBV / Sector |
1.87 / 4.71
|
| Earning Per Share | -1.29 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.96 M
GREAT
|
| Average 1W Daily Value |
2.92 M
GREAT
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
64% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-10 09:43:14 |
| Symbol | CRBU |
| Name | CARIBOU BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 99.18 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 190.43 / 8,889.42 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2929 7th Street, Berkeley, CA, United States, 94710
Phone: 510 982 6030
Website: https://cariboubio.com
Employees: 97
Sector: Healthcare >> Biotechnology
Description: Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
